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information for quality review and outcomes analyses as HCT
evolves. Databases must have speciﬁcity yet ﬂexibility in
customizing data elements. Purchased proprietary applica-
tions are used bymany HCT programs, but are limited by lack
of cost-efﬁcient conﬁgurability for center-speciﬁc needs. We
sought to develop an HCT research application allowing
evolution for program and scientiﬁc growth without major
developmental costs. We identiﬁed 5 features essential for
a functional HCT database including: 1) Uniform data
capture; 2) Center-speciﬁc adaptability; 3) Rapid report
generation; 4) Accurate, current data; and 5) Productivity
tracking.
Between August 2010 and March 2012, our team of IT
developers, programmer analysts, data managers, and
a HCT physician planned, developed, tested, and launched
a new database “BRAIN” (Blood and Marrow Transplant
Research Analysis and Information Network). This
required assessment of essential data, mapping and
migration of data from a legacy database, and interface
creation to available center systems. Legacy data was
reviewed, standardized, and imported to BRAIN. Elec-
tronic interfaces connect institutional systems including
lab results and medications via the Mofﬁtt data ware-
house to BRAIN. Additionally, discrete data such as
staging and disease prognostic factors entered by clini-
cians into the electronic medical record interface with
BRAIN reducing potential reporting errors or missing data
elements. These interfaces, along with manual abstraction,
enhance data for center speciﬁc analyses and electronic
submission to CIBMTR via AGNIS. A dashboard identifying
data manager speciﬁc CIBMTR forms due creates a proﬁ-
cient process of tracking forms. Thus, with the advance-
ment of interfaces within the application and the
mapping of this discrete data to the CIBMTR, productivity
and accuracy are enriched. To date, two forms are
submitted to the CIBMTR via AGNIS. Continuing efforts to
map AGNIS-ready forms and development of a simple
query tool will allow further growth and functionality
within the application.
BRAIN fulﬁlls a program need for cost efﬁciently, managing
evolving data, enhancing data consistency, minimizing labor
for data entry, making data easily assessable within the
institution, and ensures current and accurate data submis-
sion to outside regulatory reporting agencies.330
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Background: It is well known that female fertility is
impaired after allogeneic stem cell transplantation (SCT),
however, more female patients become long term survives,
and wish to have children of their own. Data regarding
pregnancies and child births are scarce. The aim of this
study was to determine the proportion of female patients
obtaining documented pregnancy and motherhood
following SCT.Methods: We obtained data regarding pregnancies and
child births in consecutive female transplant recipients
from our center. The patients were treated with SCT in the
period from 1976 to 2012. Data was obtained through the
national centralized access to the patients’ medical records
including specialist treatment. Patients less than 17 years
of age at the time of analysis were excluded. In total, 161
women were included in the analysis. The median age at
SCT was 17.2 years, and 31.4 years at analysis. Of the 161
women, 24 (15%) died in the observation period, the
surviving 138 women were observed median 12.3 years
(0.5-36).
Results: Of the 161 women, 20 (12.3%) had at least one
documented pregnancy (i.e. fertile). One of the 20 women
which experienced pregnancy is dead and never gave
birth. Thirteen (8%) woman obtained motherhood: 8 had
one child, 5 had two children. All children born were
healthy. Among the women with a pregnancy, 9/20 (45%)
had non-malignant hematological disease, and 11/20 (55%)
had malignant disease, among the non-fertile women the
numbers were 36/141 (25%) and 106/141 (75%), respec-
tively (P ¼ .66). Of the woman with motherhood, 7/13
(54%) had non-malignant disease, whereas 38/148 (26%) of
the remaining women had non-malignant disease (P ¼
0,029).
Total body irradiation (TBI) was given to 7 (54%) of the
women with completed delivery, at a dosage of 200 cGy in 2
and 850-1200 cGy in 5 patients.
The median age at HSCT was not different among fertile
and non-fertile women, 18.6 (2.3-33) years and 16.7 (0,2-
34,6) years respectively (P ¼ .91).
Among evaluable patients, chronic graft versus host
disease (GvHD) was documented in 4/18 (22%) of the fertile
women, and 43/116 (37%) of the non-fertile women, P ¼
0,22.
Conclusion: Not all women are infertile following alloge-
neic SCT, despite treatment with TBI chemotherapy and
chronic GvHD. However, only 8% obtained motherhood,
emphasizing the need for fertility conservation proce-
dures. The current study beneﬁts from centralized access
to patient information ensuring a high quality of accurate
and complete data.331
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The number of hematopoietic cell transplants (HCT) for
Medicare beneﬁciaries has dramatically increased, height-
ening the need to address Medicare coverage and reim-
bursement. Previous analysis of CMS claims data by ASBMT
and NMDP suggested variability by HCT programs (HCTP) in
coding and billing. Addressing these issues may be critical to
ensure ﬁnancial solvency for HCTP and continued HCT access
for Medicare beneﬁciaries.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278S276The Sarah Cannon Blood Cancer Network (SCBCN), consisting
of 5 FACT accredited HCTP, analyzed Medicare claims data
submitted by SCBCN between 1/1/11 and 12/31/11. 120 HCT
were performed on 119 patients (pts): 69 men and 50
women, median age 67 years (range 28-79) with Multiple
Myeloma (62), Lymphoma (35), Acute Leukemia (17) and
other (5). There were 23 allogeneic (allo) HCT (MS-DRG-14),
2 of which were outpatient with an average length of stay
(LOS) of 30 days (0-123) for related and 25 days (5-55) for
unrelated; 12/23 were < 20 days. Inpatient coding for
autologous (auto) HCT was split among three MS-DRG
because of a change in 2012 from MS-DRG- 15 (71) and to
MS-DRG 16dwith complication/comorbidity (cc) (18) and
MS-DRG 17dwithout cc (8) with average LOS 18 days (2-39);
55/97 were<20 days. Of 18 pts assigned DRG16, all appeared
to have codes supporting increased complexity. Of 8 pts
assigned DRG17, 5 had codes that might have supported
billing under DRG 16. Among 23 allo pts, 7 were missing the
code deﬁning donor source as related or unrelated including
both patients who received outpatient allo HCT. Revenue
code 819, which reports charges for donor cell acquisition,
was reported in 18 cases with a 40-fold variance in range of
charges. Interestingly, this code was also submitted in 46 of
97 auto cases.
Conclusion: Signiﬁcant opportunities may exist for using
the proper MS-DRG for auto pts (which has substantial
revenue implications) and the use of revenue code 819 for
allo HCT (which has substantial implications for future rate
setting). Programs can signiﬁcantly increase future
payment rates by understanding their current Medicare
billing practices and identifying opportunities for
improvement. Further investigation will focus on estima-
tion of costs as compared with reimbursement for Medi-
care beneﬁciaries.332
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Purpose: Effective training of data managers (DM) is
instrumental to assure accurate, quality data. The National
Marrow Donor Program (NMDP) and the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR)
network provide training resources and liaisons for each
transplant center in order to assist in proper completion of
the CIBMTR data collection forms. The University of Mary-
land Greenebaum Cancer Center's (UMGCC) Blood and
Marrow Transplant (BMT) team utilizes the CIBMTR elec-
tronic training resources and liaisons, as well as other alter-
native training methods. Our team was interested in
assessing the effectiveness of DM training methods and to
enhance the CIBMTR DM training model.
Method: The UMGCC BMT team developed an anonymous,
twenty-question survey on the various training methods
implemented at 138 NMDP and CIBMTR-afﬁliated transplant
centers in the U.S. The survey consisted of quantitative and
qualitative questions pertaining to demographics, prior DM
experience, and training.
Results: Seventy DMs responded to the survey. Participant
ages were well distributed with 29% of participants 18 to 34
years, 39% 35 to 49 years, and 33 % 50 to 64 years. Most
respondents (66%) reported that they had been a CIBMTR DM
for greater than 5 years. Half (51%) participated in monthly
internal assessments and 57% worked at centers thatperformed over 100 transplants per year. When asked about
training to become a DM, 51% reported having less than 1
week of training and 88% reported not being extremely
satisﬁed with his/her DM training. Thirty percent had no
previous experience with BMT-related information when
they became a DM and most (53%) were not audited prior to
independently completing CIBMTR forms. Training to
complete CIBMTR forms ranged from none to training
received from multiple sources. At the time of the survey,
54% were not familiar with the current CIBMTR training
model.
Conclusion: The CIBMTR DM Training Methods Survey
shows that CIBMTR DMs vary by age, previous experience,
and levels of training. Based on the data, it is evident that
a trainingmodel, which incorporates speciﬁc procedures and
methods, would be of value to CIBMTR DMs and the data
they report. Standardized DM training would improve the
accuracy and quality of data, which would contribute to the
knowledge learned from hematopoietic stem cell transplant
research.333
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Background: Healthcare SOPs are now standardized. There
are a few hundred routine CPL policies/procedures (P/P) and
maintaining SOP Manual (SOPM) becomes a daunting task.
SOP of any two labs would not only differ on how to achieve
the same task but no two SOPM would equally cover all
topics required by regulatory and/or accrediting agency
(R/AA).
Amongst the R/AA, JC, OSHA, CLIA, CAP, AABB, FACT & FDA
all have oversight claims on the lab, including lab practices
and SOPs. Failure to abide may result in catastrophic
outcome from citation to shut down and insurance
disapproval.
Objective: R/AA have common minimum standards-
patient safety is the prime concern, and it may be possible
to standardize R/AA requirements so that SOPM for every
CPL is identical in content, achieving uniformity across the
board.
Methods: In 2008, our CPL had a management change
and became an independent lab with a cGMP facility. We
inherited SOPs from two departments, a total of 161
policies plus 204 forms. There was confusion and dupli-
cation with two dissimilar SOPs and formats, also
previous P/P had not been updated to current regulatory
guidelines.
Early in 2010, we merged the two sets into integrated,
practical and regulatory-compliant documents with novel
formatting to distinguish one from the others. FDA regula-
tions took precedence over other R/AA.
FDA, FACT, CAP and the JC's guidelines were keenly
scrutinized prior to addressing the merger. SOPs were sorted
into three broad categories: Quality Management, Cell Pro-
cessing and cGMP.
